These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20202593)

  • 21. Therapy Insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease.
    Dooley MA; Nair R
    Nat Clin Pract Rheumatol; 2008 May; 4(5):250-7. PubMed ID: 18364720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pregnancy and assisted reproduction techniques in men and women after cancer treatment.
    Gurgan T; Salman C; Demirol A
    Placenta; 2008 Oct; 29 Suppl B():152-9. PubMed ID: 18790328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fertility preservation in cancer patients.
    Dittrich R; Maltaris T; Hoffmann I; Oppelt PG; Beckmann MW; Mueller A
    Minerva Ginecol; 2010 Feb; 62(1):63-80. PubMed ID: 20186115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus.
    Silva CA; Brunner HI
    Lupus; 2007; 16(8):593-9. PubMed ID: 17711894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients.
    Huong DL; Amoura Z; Duhaut P; Sbai A; Costedoat N; Wechsler B; Piette JC
    J Rheumatol; 2002 Dec; 29(12):2571-6. PubMed ID: 12465154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Intravenous cyclophosphamide in lupus nephritis: twenty years reducing dose].
    Frutos MA; Martín Gómez A; de Ramón E; Camps MT; Valera A; García I; Fernández Nebro A
    Nefrologia; 2007; 27(1):12-22. PubMed ID: 17402875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Female fertility preservation in autoimmune diseases: possibilities and practises in France].
    Carré-Pigeon F; Schubert B
    Gynecol Obstet Fertil; 2007 Sep; 35(9):853-60. PubMed ID: 17707674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children.
    Tangnararatchakit K; Tapaneya-Olarn C; Tapaneya-Olarn W
    J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S104-10. PubMed ID: 10730528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assisted reproduction and breast cancer.
    Sonmezer M; Atabekoglu C
    Minerva Ginecol; 2007 Aug; 59(4):403-14. PubMed ID: 17923831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis.
    Gorman C; Bhatia A; Rahman A
    Rheumatology (Oxford); 2005 Mar; 44(3):398-401. PubMed ID: 15494351
    [No Abstract]   [Full Text] [Related]  

  • 32. Strategies for preservation of ovarian and testicular function after immunosuppression.
    Pendse S; Ginsburg E; Singh AK
    Am J Kidney Dis; 2004 May; 43(5):772-81. PubMed ID: 15112167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Childhood-onset lupus nephritis: a single-center experience of pulse intravenous cyclophosphamide therapy.
    Barbano G; Gusmano R; Damasio B; Alpigiani MG; Buoncompagni A; Gattorno M; Perfumo F
    J Nephrol; 2002; 15(2):123-9. PubMed ID: 12018627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Breast cancer and fertility: critical review, considerations and perspectives].
    This P
    Bull Cancer; 2008 Jan; 95(1):17-25. PubMed ID: 18230566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
    Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M
    Lupus; 2000; 9(6):401-5. PubMed ID: 10981642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide.
    Katsifis GE; Tzioufas AG
    Lupus; 2004; 13(9):673-8. PubMed ID: 15485101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy.
    Park MC; Park YB; Jung SY; Chung IH; Choi KH; Lee SK
    Lupus; 2004; 13(8):569-74. PubMed ID: 15462485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assisted reproduction and fertility preservation techniques in cancer patients.
    Sönmezer M; Oktay K
    Curr Opin Endocrinol Diabetes Obes; 2008 Dec; 15(6):514-22. PubMed ID: 18971680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Risk factors of ovarian failure in the patients with systemic lupus erythematosus receiving cyclophosphamide therapy].
    Yang XY; Zhu X; Liang LQ; Zhan ZP; Ye YJ
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):960-2. PubMed ID: 16061002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.